Altered placental and circulating levels of vascular endothelial growth factor (VEGF) and its receptor (flt-1) may be associated with pre-eclampsia and intrauterine growth restriction (IUGR). The aim of this study was to determine whether chorionic villous VEGF or flt-1 mRNA are altered at early gestation in pregnancies subsequently found to be complicated by abnormal fetal growth. Quantitative reverse transcription-polymerase chain reaction was performed on chorionic villous samples for VEGF and flt-1 using an internal RNA standard. Using the individualized birthweight ratio (IBR), the subjects (n ⍧ 51) were divided into three groups; IUGR (IBR <10th centile, n ⍧ 6), normal (IBR 10th-90th centiles, n ⍧ 41) and macrosomic (IBR >90th centile, n ⍧ 4). There was no correlation between the mRNA expression of VEGF 121 or VEGF 165 and gestational age of the normal controls. There was also no difference in the expression of either of the VEGF isoforms between the IUGR or macrosomic groups and the normal controls. Expression of flt-1 was below the detection limit of the assay. In conclusion, we have found that altered chorionic villous expression of VEGF is not associated with the initial stages of development of IUGR or macrosomia.
Introduction
The aetiology of abnormal fetal growth, i.e. intrauterine growth restriction (IUGR) and macrosomia, is not well understood. However, it is becoming increasingly apparent that altered placental development underlies these multifactorial disorders.
From day 21 of development until the end of the first trimester, the villous vasculature undergoes an increase in the number of vessels rather than a change in type of vessels. The number of fetal red blood cell-containing capillaries increases and sprouting and branching angiogenesis from the existing capillaries give rise to a primitive capillary network surrounded by an incomplete layer of pericytes (Benirschke and Kaufmann, 1995) . Basal lamina form around the capillaries from the sixth week, resulting in a web-like arrangement of capillaries within the stroma of smaller (mesenchymal) villi, while in larger villi (immature intermediate) most of the capillaries are superficial. In these larger villi, a few early villous arteries and veins are located centrally, and from the 15th week, the adventitia of these central arteries fuse as the stem villous forms (Demir et al., 1997) . From 26 weeks of gestation until term, the villous vascular growth undergoes a change from branching to nonbranching angiogenesis owing to the formation of the mature intermediate villi that specialize in gas exchange. These form at the tips of the villous trees and are long and slender, containing one or two long, poorly branched capillary loops (Dunk and Ahmed, 2000) .
The type of angiogenesis occurring is dependent in part on the concentration ratio of the angiogenic growth factors, vascular endothelial growth factor (VEGF) to placental growth factor (PlGF). VEGF exerts its effects by binding with high affinity to two tyrosine kinase receptors VEGFR-1/flt-1 and VEGFR-2/KDR (de Vries et al., 1992; Terman et al., 1992) . In primary isolates of first trimester trophoblast cells and in a first trimester extravillous trophoblast cell line, the VEGFR-1/ flt-1 receptor is expressed, as detected by reverse transcriptionpolymerase chain reaction (RT-PCR) (Lash et al., 1999) . In human placenta, VEGF expression has been analysed by in-situ hybridization and immunohistochemical techniques and has been demonstrated to be localized to the villous trophoblast and macrophages of both fetal and maternal origin (Ahmed et al., 1995; Shore et al., 1997) . A recent study on the expression of VEGF, VEGFR-1, VEGFR-2/KDR and VEGFR-3/flt-4 in the placentae of normotensive women demonstrated by immunohistochemistry that VEGF and VEGFR-2 were localized to the endothelial cells of capillaries in the villi and of larger vessels (Helske et al., 2001) . VEGFR-1 and VEGFR-3 were localized to the syncytial layer of the chorionic villi. VEGFR-1 was also localized to the placental endothelial cells. PlGF shares 53% homology with VEGF and is expressed both in the villous syncytiotrophoblast and in the media of larger placental stem vessels (Shore et al., 1997; Dunk and Ahmed, 2000) . As VEGF is known to act in a paracrine manner on endothelial cells, it seems likely to be involved in the initiation of placental vasculogenesis. Correlation of the effects of the growth factors (Dunk and Ahmed, 2000) and their expression patterns throughout gestation Leiser et al., 1985) have suggested that VEGF and VEGFR-2/KDR are involved in the first two trimesters of pregnancy in the establishment of the richly branched capillary beds of the mesenchymal and intermediate villi, whereas PlGF and flt-1 are more likely to be involved in the formation of the long poorly branched terminal capillary loops in the last trimester.
It appears that there may be two phenotypes of IUGR. In one phenotype, the placenta appears to be in a state of relative hypoxia and in the other, severe early-onset IUGR, it appears to be in a state of hyperoxia (Kingdom and Kaufmann, 1999) . In the majority of placentae from women with IUGR there is morphological evidence of continued branching angiogenesis. However, in a small subset of women with severe early-onset IUGR, there is reduced fetal-placental blood flow resulting in or from elongated maldeveloped villous capillaries (Kohnen and Kingdom, 2000) .
Macrosomia (or large for gestational age infants) may be associated with diabetes and the majority of investigations have concentrated on insulin, the insulin-like growth factors I and II and their binding proteins. However, very little consideration has been given to the idea of altered placentation as a possible underlying factor of macrosomia in pregnancies not complicated by diabetes. It is possible that inappropriate placental development is associated with non-diabetes-associated macrosomia.
In this study, we have attempted to measure the expression of VEGF and flt-1 mRNA in first and second trimester placental tissue from normal pregnancies and from pregnancies complicated by IUGR or macrosomia. The only ethically acceptable method of obtaining tissue was to use that surplus to diagnostic purposes, after chorionic villous sampling.
Materials and methods

Patient details
Written consent was obtained from women attending Nottingham City Hospital for diagnostic first trimester chorionic villous sampling. In the majority of cases, sampling was on the basis of increased maternal age; occasionally patients were sampled due to a previous child having had chromosomal abnormalities. Approximately 10 mg of tissue was removed for cytogenetic studies, and tissue surplus to these requirements was utilized in the study. Using the individualized 1094 birth ratio (IBR) (Wilcox et al., 1993) , the patients were divided into three groups; IBR Ͻ10th centile, IBR 10th-90th centile, IBR Ͼ90th centile. Patient demographics for the three groups are shown in Table I . The IBR is a ratio relative to a predicted birthweight, calculated using independent coefficients for gestation at delivery, fetal sex, parity, ethnic origin, maternal height and booking weight. This ratio enables a more accurate prediction of pregnancy outcome than birthweight for gestational age alone. All women in the study were Caucasian and there was a normal distribution of fetal sex within each group. None of the patients had diabetes mellitus. None of the IUGR pregnancies were complicated by early onset disease (Ͻ32 weeks) or Doppler umbilical artery absent end-diastolic flow.
Sample collection
Tissue samples that were surplus to clinical diagnostic requirements were collected into liquid nitrogen following the sampling procedure and stored until required for analysis. Samples were collected over a 3 year period; however, there was no difference in the average storage time for the three groups.
RNA extraction
Total RNA was isolated from the chorionic villous tissue samples using the Purescript RNA isolation kit (Flowgen, Staffordshire, UK) following the manufacturer's instructions for tissue samples.
RT-PCR
First strand cDNA was synthesized using the Reverse-iT kit (Advanced Biotechnology Ltd, UK) which utilizes Murine Molony Leukemia Virus (MMLV) reverse transcriptase and an anchored oligo dT primer. Approximately 1 µg of total RNA was used in the RT reaction.
RT-PCR was performed for β-actin and HLA-G (Kirszenbaum et al., 1994 ) using the primer pairs described in Table II . A standard PCR reaction mix was used to amplify 2 µl of each cDNA sample using a PCR master mix (Advanced Biotechnology Ltd, UK) with a final concentration of 2.0 mmol/l MgCl 2 and 0.2 µl of each primer (50 pmol/l starting concentration). The PCR for HLA-G was a seminested reaction, first using the 257 and 1225 primer pair and secondly amplifying 2 µl of the first round product with the 526 and 1225 primer pair. In both cases, 35 cycles of denaturation, annealing and extension were performed.
Quantitative RT-PCR
Constructs for standard artificial mRNA (construct mRNA, cRNA) for VEGF and flt-1 were made in pBlueScript (Stratagene, Amsterdam, NL). A schematic diagram for the design of both constructs is shown in Figure 1 . A three-step cloning protocol was used for the insertion of each component of the construct. Oligonucleotides were made for the complementary and identical sequences for the primers to be used with appropriate restriction site sequences at their ends for ease in cloning. The reverse primer oligonucleotide also contained a polyT stretch to produce a polyA tail in the resultant RNA for use in the reverse transcriptase reaction. Stuffer DNA from lambda DNA was used to give the construct its expected length, i.e. suitably different from the wild type PCR product length to be distinguished from it during electrophoresis, but close enough that both the construct and unknown product were amplified under the same kinetics. At each step of the cloning procedure, clones were verified by sequence analysis (ABI automated sequencer unit, Department of Biochemistry, University of Nottingham, UK).
RNA was produced from the plasmids containing each construct using a T3 RNA polymerase assay (Promega, Southampton, UK) and measured spectrophotometrically to determine the concentration of the cRNA. Different concentrations of the cRNA were reverse- Data are shown as median (interquartile range). There was no statistical difference between the Ͻ10th centile or Ͼ90th centile groups and the 10th-90th centile group for any of the factors apart from fetal weight at birth and IBR centile; *P Ͼ 0.001, Mann-Whitney U-test. transcribed as previously described and used in a PCR reaction to determine the optimum concentration of cRNA to use in each of the VEGF and flt-1 experiments. The optimum concentration of cRNA for VEGF and ftl-1 was added to 1 µg of RNA for each sample and reverse-transcribed as described earlier. VEGF mRNA was amplified using two primer pairs (Table II) in a nested PCR reaction. Two µl of cDNA for each sample was added to a PCR master mix as previously described and one in three serial dilutions were performed such that there were six reactions for each sample. In the PCR for VEGF, 30 cycles were performed in the first round with the I ϩ J primer pair and a subsequent 19 cycles were performed in the second round with the C ϩ H primer pair using 2 µl of the first round product. The VEGF-C primer was tagged with a Cy5 molecule for use in an ALF sequencer. In the flt-1 PCR, 1095 30 cycles were performed and the forward primer was tagged with a Cy5 molecule for use in an ALF sequencer. All products were run on a polyacrylamide gel and visualized with an ALF sequencer. The intensity of fluorescence for each product was assessed as the area under a curve as determined by the ALF software. The area under the curve for each product in each sample was plotted against the dilution factor on a log-log plot to obtain the ratio of sample to construct. This ratio was then applied to the known amount of cRNA added to the RT reaction and expressed as the pg mRNA/µg total RNA in the sample.
Results
β-actin and HLAG RT-PCR
Initially 127 samples were collected for analysis. All of these were screened by RT-PCR for the presence of β-actin. Of the initial 127 samples, 75 had a product for β-actin when run on an ethidium bromide agarose gel. Unfortunately there was insufficient patient data to determine the pregnancy outcome or IBR, or the pregnancy in 24 of these cases had been terminated due to detected chromosomal abnormalities. The remaining 51 samples were studied for the presence of HLA-G by RT-PCR to determine the presence of trophoblast tissue within the sample. All samples tested positive for HLA-G, a specific marker of trophoblast cells.
VEGF quantitative RT-PCR
A typical graph of PCR band intensity obtained from the ALF sequencer is shown in Figure 2 . There was no correlation between the mRNA expression of VEGF 121 (Figure 3) or VEGF 165 (Figure 4 ) and the gestational age of the normal controls [gestation range 9 to 18 ϩ 6 weeks, VEGF 121 , P ϭ (Figure 6 ) and the gestational age of the IUGR [gestation range 6 ϩ 4 to 19 ϩ 4 weeks, VEGF 121 P ϭ 0.7, r 2 ϭ 0.04; VEGF 165 , P ϭ 0.7, r 2 ϭ 0.09 (Spearman correlation)] or macrosomia [gestation range 11 ϩ 2 to 13 ϩ 3 weeks, VEGF 121 P ϭ 0.7, 1096 r 2 ϭ 0.04; VEGF 165 , P ϭ 0.7, r 2 ϭ 0.09 (Spearman correlation)] pregnancies.
There was no significant difference in the expression of either of the VEGF isoforms between the IUGR or macrosomic groups and the normal controls [VEGF 121 : IUGR, 0.06 (0.02-0.09) (P ϭ 0.2, Mann-Whitney U-test), normal, 0.15 (0.02-0.27), macrosomic, 0.12 (0.06-0.2) (P ϭ 0.6, Mann-Whitney U-test); VEGF 165 : IUGR, 0.09 (0.03-0.23) (P ϭ 0.2, MannWhitney U-test), normal, 0.34 (0.04-0.53), macrosomic, 0.27 (0.16-0.39) (P ϭ 0.6, Mann-Whitney U-test)] (Figures 5  and 6 ).
flt-1 quantitative RT-PCR
The level of flt-1 in all of the samples (n ϭ 51) was below the level of detection of the assay system.
Discussion
This study investigated the expression of two isoforms of VEGF-A, 165 and 121, and one of their receptors, VEGFR-1/ flt-1, in first and second trimester placental tissue in pregnancies complicated by abnormal fetal and placental growth (IUGR and macrosomia). VEGFR-1/flt-1 mRNA expression in the chorionic villous samples was below the level of detection of the assay system. We found no correlation between infant size at birth and VEGF expression. We also found no evidence of altered VEGF expression with gestation in the early stages of pregnancy.
Recently, it has been demonstrated that there is no difference in the intensity or localization of staining for VEGF between placental sections from women with pre-eclampsia or IUGR those from normal pregnancies (Helske et al., 2001) . They did, however, observe an increase in the intensity of staining for VEGFR-1/flt-1, but not for VEGFR-2 or VEGFR-3, in a proportion of the same groups of affected placentae compared with normal placentae. Additionally, the related protein, PlGF, has been shown to increase in term placentae complicated by fetal growth restriction (Khaliq et al., 1999) . In contrast, serum PlGF has been shown to be lower in women with pre-eclampsia or IUGR compared to normal controls at term (Helske et al., 2001) . It would be interesting to repeat this study to investigate the expression of PlGF in these samples and to determine if the previously reported increase in expression of this growth factor at term is an effect of IUGR or a cause of it. The six cases of IUGR in the study had late onset disease, a condition characterized by increased branching angiogenesis (Kohnen and Kingdom, 2000) . VEGF has been reported to be important for branching angiogenesis, whereas PlGF has been shown to be associated with non-branching angiogenesis. We would thus have anticipated an increase in VEGF expression. Although the sample size in this study was low, the results do not support a role for chorionic villus-derived VEGF in the pathogenesis of the condition. It would be interesting to investigate samples from women with early-onset IUGR, given the likelihood of a different aetiology of this disease.
In previous reports, increased levels of serum VEGF have been associated with pre-eclampsia (Baker et al., 1995; Sharkey et al., 1996; Kupferminc et al., 1997; Brockelsby et al., 1999) . Several other studies have found depressed levels of VEGF in the sera of pre-eclamptic women (Lyall et al., 1997; Reuvekamp et al., 1999) , although the discrepancies may be explained by the fact that quantification of VEGF in pregnancy is affected by interference from binding proteins (Anthony et al., 1997) . A decrease in placental VEGF mRNA in women with preeclampsia has been demonstrated ; however, another study found no difference in placental VEGF protein levels between normotensive and pre-eclamptic pregnancies (Helske et al., 2001) . These studies have been conducted at term or on clinical presentation of the condition, and it is likely therefore that these altered levels may be an effect of the inefficient placentation rather than the cause of it. The small sample size, resulting from inadequate tissue for analysis and in some cases inadequate patient details is an important caveat in the interpretation of our results. It would have been optimal to collect multiple samples from the same women over gestation, and so due to the nature of the tissue collection this was not possible, but we may not have collected a truly representative sample of chorionic villi from each woman. A second caveat that should be placed on this study is how representative the samples obtained are of the population as a whole. Although advancing maternal age increases the incidence of pre-eclampsia, it is likely that we did not sample any women with pre-eclampsia as the increased maternal age meant that the majority of subjects were multiparous.
This study has indicated that chorionic villi VEGF mRNA levels do not increase early in gestation, over a period when oxygen tension is rising in the placenta and one would expect to see an increase in VEGF mRNA. Nor could we find any evidence for the role of chorionic villi VEGF expression in the early placenta of pregnancies later complicated by fetal growth abnormalities such as IUGR or macrosomia. It is possible, however, that altered maternal myometrial or decidual VEGF production may lead to these conditions. One of the receptors for VEGF, VEGFR-1/flt-1, was not detectable in any of the samples studied. The study of the other receptors for VEGF and the expression of PlGF in similar samples and in samples of maternal myometrium and decidua would be very interesting. Further research is required on the factors involved in early placental development.
